Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7635626 | 1.00 | RAB9A (0.46) | RAB9ANPC1HTTCYP1A2CYP3A4 | |
| SCHEMBL7630186 | 0.81 | MAPT (0.44) | RAB9ANPC1HTTCYP1A2CYP3A4 | |
| SCHEMBL7630182 | 0.81 | MAPT (0.44) | RAB9ANPC1HTTCYP1A2CYP3A4 | |
| SCHEMBL4259969 | 0.81 | MAPT (0.44) | RAB9ANPC1HTTCYP1A2CYP3A4 | |
| SCHEMBL7639079 | 0.78 | NPC1 (0.49) | RAB9ANPC1HTTCYP1A2CYP3A4 | |
| SCHEMBL7639084 | 0.78 | NPC1 (0.49) | RAB9ANPC1HTTCYP1A2CYP3A4 | |
| SCHEMBL7632826 | 0.76 | MAPT (0.46) | RAB9ANPC1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7632816 | 0.76 | MAPT (0.46) | RAB9ANPC1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8809159 | 0.73 | POLB (0.54) | RAB9ANPC1HTTCYP1A2CYP3A4 | |
| SCHEMBL8810370 | 0.73 | POLB (0.54) | RAB9ANPC1HTTCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6365609-B1 | MODULATORS FOR ATP-REGULATED POTASSIUM CHANNELS; TREATING DIABETES OR HYPERINSULINEMIA | NOVO NORDISK A/S (DK) | 2002-04-02 | — | — | US | claimed |
| US-6362205-B2 | FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR SYSTEM DISORDERS, PULMONARY SYSTEM DISORDERS, GASTROINTESTINAL SYSTEM DISORDERS, AND ENDOCRINOLOGIC SYSTEM DISORDERS | NOVO NORDISK A/S (DK) | 2002-03-26 | — | — | US | claimed |
| US-6365609-B1 | MODULATORS FOR ATP-REGULATED POTASSIUM CHANNELS; TREATING DIABETES OR HYPERINSULINEMIA | NOVO NORDISK A/S (DK) | 2002-04-02 | — | — | US | disclosed |
| US-6362205-B2 | FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR SYSTEM DISORDERS, PULMONARY SYSTEM DISORDERS, GASTROINTESTINAL SYSTEM DISORDERS, AND ENDOCRINOLOGIC SYSTEM DISORDERS | NOVO NORDISK A/S (DK) | 2002-03-26 | — | — | US | disclosed |
| US-20010056188-A1 | Substituted 3,3-diamino-2-propenenitriles, their preparation and use | HANSEN JOHN BONDO (DK) | 2001-12-27 | — | — | US | disclosed |
| US-20010025111-A1 | Substituted 3,3-diamino-2-propenenitriles, their preparation and use | HANSEN JOHN BONDO (DK) | 2001-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056188-A1 | Substituted 3,3-diamino-2-propenenitriles, their preparation and use | TNNI3, PCCA, NPR3 | RAB9A 3761/4885NPC1 3348/4885HTT 1895/4885 |
| US-20010025111-A1 | Substituted 3,3-diamino-2-propenenitriles, their preparation and use | NPR3, NPR1, PKD1 | RAB9A 3077/4885NPC1 2952/4885HTT 3377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.